AtaiBeckley Inc. will hold a Virtual Investor Day on March 6, 2026, featuring presentations from executives and experts.
Quiver AI Summary
AtaiBeckley Inc. announced a Virtual Investor Day scheduled for March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET, aimed at showcasing the company’s efforts in developing innovative mental health treatments. The event will feature presentations and Q&A sessions with the executive team and external experts, and it's open to investors, analysts, and media. Participants can register for the live webcast, and a replay will be available afterward. AtaiBeckley is focused on creating rapid-acting and effective therapies for mental health conditions, including treatments for treatment-resistant depression and social anxiety disorder, with various candidates in different stages of clinical development. More details about the company and its mission can be found on their website.
Potential Positives
- The company is hosting a Virtual Investor Day, indicating proactive engagement with investors and transparency about its operations and future plans.
- The event will feature presentations from the executive leadership team and key opinion leaders, which can enhance credibility and showcase expertise in the field.
- AtaiBeckley is advancing multiple therapies in its pipeline, including promising treatments for mental health conditions such as treatment-resistant depression and social anxiety disorder.
- The company is actively engaging in drug discovery for non-hallucinogenic treatments, indicating a commitment to innovation and addressing significant healthcare needs.
Potential Negatives
- The company is still in clinical stages, indicating that it has not yet brought any products to market, which could raise concerns about its long-term viability and the effectiveness of its pipeline.
- Details regarding the specific results or progress of their therapies in Phase 2 and Phase 3 stages are lacking, potentially leading to investor skepticism about the success rates of these projects.
- The invitation to a Virtual Investor Day may indicate the need for additional engagement with investors, suggesting that the company could be struggling to maintain investor confidence or interest.
FAQ
When is AtaiBeckley’s Virtual Investor Day?
AtaiBeckley’s Virtual Investor Day is scheduled for March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET.
How can I register for the event?
Investors, analysts, and media members can register for the event via the provided registration link: https://app.webinar.net/7e5Jn1zYlXj.
What will be presented during the Virtual Investor Day?
The event will feature presentations and live Q&A sessions with the executive leadership team and key opinion leaders.
Will there be a replay of the event available?
Yes, a replay of the Virtual Investor Day will be accessible on the investor section of the AtaiBeckley website after the event.
What is AtaiBeckley focused on developing?
AtaiBeckley is focused on transforming mental health treatments with rapid-acting, durable, and convenient solutions for patients.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ATAI Insider Trading Activity
$ATAI insiders have traded $ATAI stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ATAI stock by insiders over the last 6 months:
- COSMO FEILDING-MELLEN sold 39,594 shares for an estimated $154,377
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ATAI Hedge Fund Activity
We have seen 69 institutional investors add shares of $ATAI stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 7,677,289 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $31,400,112
- DEEP TRACK CAPITAL, LP added 4,677,289 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,130,112
- BLACKROCK, INC. added 2,808,808 shares (+63836.5%) to their portfolio in Q4 2025, for an estimated $11,488,024
- FORESITE CAPITAL MANAGEMENT VI LLC added 2,750,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $11,247,500
- RTW INVESTMENTS, LP added 2,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,180,000
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,936,267 shares (-99.8%) from their portfolio in Q4 2025, for an estimated $7,919,332
- AMERIPRISE FINANCIAL INC added 1,735,252 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,097,180
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ATAI Analyst Ratings
Wall Street analysts have issued reports on $ATAI in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 01/20/2026
- Canaccord Genuity issued a "Buy" rating on 10/22/2025
- Needham issued a "Buy" rating on 10/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/23/2025
To track analyst ratings and price targets for $ATAI, check out Quiver Quantitative's $ATAI forecast page.
$ATAI Price Targets
Multiple analysts have issued price targets for $ATAI recently. We have seen 5 analysts offer price targets for $ATAI in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Eddie Hickman from Guggenheim set a target price of $11.0 on 01/20/2026
- Justin Walsh from Jones Trading set a target price of $16.0 on 12/23/2025
- Sumant Kulkarni from Canaccord Genuity set a target price of $14.0 on 10/22/2025
- Ami Fadia from Needham set a target price of $12.0 on 10/13/2025
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $15.0 on 09/23/2025
Full Release
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will feature presentations and live Q&A sessions with members of the Company’s executive leadership team and several external key opinion leaders.
Investors, analysts, and members of the media are invited to register for the live webcast. A replay will be made available following the event on the investor section of the AtaiBeckley website, under Events .
Registration Link: https://app.webinar.net/7e5Jn1zYlXj
About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X .
Contact Information:
Investors:
Jason Awe, PhD
VP, Investor Relations
[email protected]
Media:
Charlotte Chorley
Associate Director, Communications
[email protected]
